Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amivantamab plus standard of care versus standard of care for first-line recurrent/metastatic head and neck squamous cell carcinoma
NL-OMON60663Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial in head and neck squamous cell carcinoma (HNSCC) comparing Amivantamab plus standard of care with Standard of care (2 arms). Primary endpoint: Overall survival. Started Jul 2026; status: recruiting.
02
Drugs
amivantamab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NL-OMON60663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60663.